Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Thompson
P A
PA
Prince
H M
HM
Seymour
J F
JF
Ritchie
D
D
Stokes
K
K
Burbury
K
K
Wolf
M
M
Peinert
S
S
Joyce
T
T
Harrison
S J
SJ
D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D011719:Pyrazines / Q000008:administration & dosage*; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan